Galaxy Medicare (NSE:GML) 5-Year EBITDA Growth Rate: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GML Galaxy Medicare Ltd NSE:GML
20 GF Score
Price ₹17.85
! 2 Warning Signs
View Full Analysis

What is Galaxy Medicare 5-Year EBITDA Growth Rate?

Galaxy Medicare NSE:GML 20 5-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates NSE:GML with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Galaxy Medicare's EBITDA per Share for the six months ended in Mar. 2026 was ₹1.55.

During the past 12 months, Galaxy Medicare's average EBITDA Per Share Growth Rate was -1.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 11.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Galaxy Medicare was 45.20% per year. The lowest was 11.10% per year. And the median was 28.15% per year.

Galaxy Medicare  (NSE:GML) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Galaxy Medicare 5-Year EBITDA Growth Rate Related Terms

NSE:GML vs ISRG, BDX, RMD: 5-Year EBITDA Growth Rate Comparison

For the Medical Instruments & Supplies subindustry, Galaxy Medicare's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galaxy Medicare 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Galaxy Medicare's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Galaxy Medicare's 5-Year EBITDA Growth Rate falls into.


NSE:GML
20GF Score
Galaxy Medicare Ltd NSE:GML
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galaxy Medicare 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Galaxy Medicare (NSE:GML) has a 5-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Galaxy Medicare and its competitors.
Is Galaxy Medicare's 5-Year EBITDA Growth Rate too high?
Galaxy Medicare's current 5-Year EBITDA Growth Rate is 0.00%. Overall, Galaxy Medicare has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Galaxy Medicare's 5-Year EBITDA Growth Rate compare to ISRG and BDX?
Galaxy Medicare's 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Galaxy Medicare and its competitors. Galaxy Medicare's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galaxy Medicare stock overvalued right now?
Galaxy Medicare (NSE:GML) has a current 5-Year EBITDA Growth Rate of 0.00%. The current 5-Year EBITDA Growth Rate is 0.00%. Galaxy Medicare's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Galaxy Medicare (NSE:GML), the current 5-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galaxy Medicare Business Description

Address Plot No-2, Zone D, Phase A, Mancheswar Industrial Estate, Khurda, Bhubaneswar, OR, IND, 751010
Galaxy Medicare Ltd is engaged into the manufacturing, trading and exporting of Medical Devices, Plasters of Paris Bandages (POP Bandage) and Other surgical dressings in India. Its business encompass: Manufacturing and Branding of its own products under its flagship brands i.e. POP BAND, POP CAST, G CAST, GYPSOSOFT, GYPSOPLAST, CARETAPE, GYPSOCREPE, CARECREPE, CAREPORE GYPSONET, GYPSOCHLOR, FIXCAN ETC.
20GF Score

Get the complete analysis for NSE:GML

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹17.85
Price